Complement, Fc receptors and antibodies: A Trojan horse in HIV infection?

Current Opinion in HIV and AIDS

Volumn 4, Issue 5, 2009, Pages 394-399

  Stoiber, Heribert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Complement; HIV; Neutralizing antibody; T cell infection

Indexed keywords

COMPLEMENT; EPITOPE; FC RECEPTOR; NEUTRALIZING ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; MASKING; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RETROVIRUS INFECTION; REVIEW; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODY-DEPENDENT ENHANCEMENT; COMPLEMENT SYSTEM PROTEINS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; RECEPTORS, FC;

EID: 69549127929     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32832f0108     Document Type: Review

References (90)

1. Huber M, Olson WC, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Int Med 2007; 262:5-25. (Pubitemid 47000630)
2. Willey S, Aasa-Chapman MM. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol 2008; 16:596-604. This comprehensive review focuses on effector functions of non-neutralizing antibodies. Complement and FcR-related aspects are highlighted.
3. Huber M, Olson WC, Trkola A. Antibodies for HIV treatment and prevention: window of opportunity? Curr Top Microbiol Immunol 2008; 317:39-66. In this study, not only the potential benefit of neutralizing antibodies against the envelope proteins are discussed, but also antibodies against alternative vaccine targets (cellular receptors etc) are critically analyzed.
4. Huber M, Fischer M, Misselwitz B, et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006; 3:e441. (Pubitemid 44875941)
5. Aasa-Chapman MM, Holuigue S, Aubin K, et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005; 79:2823-2830. (Pubitemid 40270560)
6. Wilflingseder D, Banki Z, Dierich MP, Stoiber H. Mechanisms promoting dendritic cell-mediated transmission of HIV. Mol Immunol 2005; 42:229-237. (Pubitemid 39361451)
7. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 2008; 26:3046-3054. This review follows the fate of HIV and complement from the viral entry to the development of AIDS.
8. Beck Z, Prohászka Z, Füst G. Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development. Vaccine 2008; 26:3078-3085.
9. Bánki Z, Stoiber H, Dierich MP. HIV and human complement: inefficient virolysis and effective adherence. Immunol Lett 2005; 97:209-214. (Pubitemid 40326953)
10. Stoiber H, Pruenster M, Ammann CG, Dierich MP. Complement-opsonized HIV: the free rider on its way to infection. Mol Immunol 2005; 42:153-160.
11. Stoiber H, Clivio A, Dierich MP. Role of complement in HIV infection. Ann Rev Immunol 1997; 15:649-674.
12. Stoiber H, Kacani L, Speth C, et al. The supportive role of complement in HIV pathogenesis. Immunol Rev 2001; 180:168-176. (Pubitemid 32472861)
13. Kimura A, Sakaguchi E, Nonaka M. Multicomponent complement system of Cnidaria: C3, Bf, and MASP genes expressed in the endodermal tissues of a sea anemone, Nematostella vectensis. Immunobiology 2009; 214:165-178.
14. Speth C, Prodinger WM, Würzner R, et al. Complement. In: Paul WE, editor. Fundamental immunology, 6th ed. PA: Lippincott-Raven Publishers; 2008. pp. 1047-1078. A comprehensive and very recent published summary of the current knowledge in the complement field.
15. Ebenbichler CF, Thielens NM, Vornhagen R, et al. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991; 174:1417-1424.
16. Spear GT, Jiang HX, Sullivan BL, et al. Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 1991; 7:579-585.
17. Thielens NM, Bally IM, Ebenbichler CF, et al. Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1. J Immunol 1993; 151:6583-6592.
18. Stoiber H, Thielens NM, Ebenbichler C, et al. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology. Eur J Immunol 1994; 24:294-300. (Pubitemid 24978152)
19. Ji X, Gewurz H, Spear GT. Mannose binding lectin (MBL) and HIV. Mol Immunol 2005; 42:145-152. (Pubitemid 39361445)
20. Spear GT, Takefman DM, Sullivan BL, et al. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993; 67:53-59. (Pubitemid 23002963)
21. Sullivan NJ. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 2001; 260:145-169.
22. Sullivan BL, Knopoff EJ, Saifuddin M, et al. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo. J Immunol 1996; 157:1791-1798. (Pubitemid 126449124)
23. Wilfingseder D, Spruth M, Ammann CG, et al. Complement-mediated enhancement of HIV-1 neutralisation by anti-HLA antibodies derived from polytransfused patients. Int Arch Allergy Immunol 2003; 131:62-72. (Pubitemid 36649360)
24. Huber M, von Wyl V, Ammann CG, et al. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008; 82:3834-3842. In this study the neutralizing capacity of passively administered nAbs was analyzed and correlated with the induction of complement-mediated lysis. In some but not all cases, neutralization did not correlate with complement activation.
25. Frank I, Stoiber H, Godar S, et al. Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996; 10:1611-1620. (Pubitemid 26394978)
26. Dierich MP, Stoiber H, Clivio A. A 'complement-ary' AIDS vaccine. Nat Med 1996; 2:153-155.
27. Stoiber H, Pinté r C, Siccardi AG, Clivio A, et al. Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996; 183:307-310. (Pubitemid 26028772)
28. Stoiber H, Ammann C, Spruth M, Mullauer B, et al. Enhancement of complement-mediated lysis by a peptide derived from SCR 13 of complement factor H. Immunobiology 2001; 203:670-686. (Pubitemid 32479434)
29. Nimmerjahn F, Ravetch JV. Fcγ receptors: old friends and new family members. Immunity 2006; 24:19-28. (Pubitemid 43077197)
30. Gómez-Román VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174:2185-2189.
31. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449:101-104. (Pubitemid 47373775)
32. Sawyer LA, Katzenstein DA, Hendry RM, et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990; 6:341-356.
33. Forthal DN, Landucci G, Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 2001; 17:553-561. (Pubitemid 32692337)
34. Alsmadi O, Herz R, Murphy E, et al. A novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infection. J Virol 1997; 71:925-933. (Pubitemid 27030262)
35. Lyerly HK, Reed DL, Matthews TJ, et al. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987; 3:409-422.
36. Florese RH, Van Rompay KK, Aldrich K, et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 2006; 177:4028-4036. (Pubitemid 44359936)
37. Ahmad A, Yao XA, Tanner JE, et al. Surface expression of the HIV-1 envelope proteins in env gene-transfected CD4-positive human T cell clones: characterization and killing by an antibody-dependent cellular cytotoxic mechanism. J Acquir Immune Defic Syndr 1994; 7:789-798. (Pubitemid 2113136)
38. Klasse PJ, Moore JP. Is there enough gp120 in the body fluids of HIV-1-infected individuals to have biologically significant effects? Virology 2004; 323:1-8.
39. Eger KA, Unutmaz D. Perturbation of natural killer cell function and receptors during HIV infection. Trends Microbiol 2004; 12:301-303. (Pubitemid 38829648)
40. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80:6177-6181. (Pubitemid 43849196)
41. Wilflingseder D, Banki Z, Garcia E, et al. IgG-opsonisation of HIV impedes integration in and infection of DCs and subsequent long-term transfer to T cells. J Immunol 2007; 178:7840-7848. (Pubitemid 46898056)
42. Sullivan BL, Takefman DM,Spear GT. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 1998; 248:173-181.
43. Scherl M, Posch U, Obermoser G, et al. Targeting human immunodeficiency virus type 1 with antibodies derived from patients with connective tissue disease. Lupus 2006; 15:865-872. (Pubitemid 46049691)
44. Nemerow GR, Cooper NR. Isolation of Epstein-Barr virus and studies of its neutralization by human IgG and complement. J Immunol 1981; 127:272-278.
45. Bergthaler A, Flatz L, Verschoor A, et al. Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol 2009; 7:e80 [Epub ahead of print]. This elegant study shows that even early non-neutralizing but virus-specific IgM impedes viral persistence during LCMV infection in a mouse model.
46. Rabinovitch M. Professional and nonprofessional phagocytes: an introduction. Trends Cell Biol 1995; 5:85-87.
47. Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol 1991; 3:76-82.
48. Kedzierska K, Azzam R, Ellery P, et al. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol 2003; 26:247. (Pubitemid 36206609)
49. Bender BS, Davidson BL, Kline R, et al. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 1988; 10:1142-1154.
50. Monari C, Casadevall A, Pietrella D, et al. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fcγ receptor function. J Infect Dis 1999; 180:1542-1549.
51. Thomas CA, Weinberger OK, Ziegler BL, et al. Human immunodeficiency virus-1 env impairs Fc receptor-mediated phagocytosis via a cyclic adenosine monophosphate-dependent mechanism. Blood 1997; 90:3760-3765.
52. Azzam R, Kedzierska K, Leeansyah E, et al. Impaired complement-mediated phagocytosis by HIV type-1-infected human monocyte-derived macrophages involves a cAMP-dependent mechanism. AIDS Res Hum Retroviruses 2006; 22:619-629. (Pubitemid 44061398)
53. Mouhoub A, Delibrias CC, Fischer E, et al. Ligation of CR1 (C3b receptor, CD35) on CD4+ 3T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 1996; 106:297-303. (Pubitemid 26359896)
54. June RA, Schade SZ, Bankowski MJ, et al. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991; 5:269-274.
55. Zhou J, Montefiori DC. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Virology 1996; 226:13-21. (Pubitemid 26414390)
56. Robinson WE Jr, Montefiori DC, Mitchell WM. Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990; 175:600-604.
57. Robinson WE Jr, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 1:790-794. (Pubitemid 18094913)
58. Tremblay M, Meloche S, Sekaly RP, Wainberg MA. Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med 1990; 171:1791-1796. (Pubitemid 20167568)
59. Gras G, Richard Y, Roques P, et al. Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 1993; 81:1808-1818. (Pubitemid 23101594)
60. Delibrias CC, Mouhoub A, Fischer E, Kazatchkine MD. CR1 (CD35) and CR2 (CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 1994; 24:2784-2788. (Pubitemid 24342197)
61. Toth FD, Mosborg-Petersen P, Kiss J, et al. Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol 1994; 96:389-394. (Pubitemid 24224855)
62. Boyer V, Desgranges C, Trabaud MA, et al. Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 1991; 173:1151-1158.
63. Pruenster M, Wilflingseder D, Bánki Z, et al. C-type lectin-independent interaction of complement opsonized HIV with monocyte-derived dendritic cells. Eur J Immunol 2005; 35:2691-2698. (Pubitemid 41404052)
64. Bouhlal H, Chomont N, Réquena M, et al. Opsonization of HIV with complement enhances infection of dendritic cells and viral transfer to CD4 T cells in a CR3 and DC-SIGN-dependent manner. J Immunol 2007; 178:1086-1095. (Pubitemid 46095182)
65. Hussain LA, Kelly CG, Rodin A, et al. Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium. Clin Exp Immunol 1995; 102:384-388.
66. Takeda A, Tuazon CU, Ennis FA. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242:580-583. (Pubitemid 18263201)
67. Laurence J, Saunders A, Early E, Salmon JE. Human immunodeficiency virus infection of monocytes: relationship to Fc-gamma receptors and antibody-dependent viral enhancement. Immunology 1990; 70:338-343. (Pubitemid 20212245)
68. Kozlowski PA, Black KP, Shen L, Jackson S. High prevalence of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons. Masking by IgG. J Immunol 1995; 154:6163-6173.
69. Brouwer KC, Lal RB, Mirel LB, et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004; 18:1187-1194.
70. Forthal DN, Gilbert PB, Landucci G, et al. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178:6596-6603. (Pubitemid 46717444)
71. Forthal DN, Landucci G, Bream J, et al. Fcγ RIIa genotype predicts progression of HIV infection. J Immunol 2007; 179:7916-7923.
72. Hess C, Klimkait T, Schlapbach L, et al. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002; 359:2230-2234. (Pubitemid 34717976)
73. Horakova E, Gasser O, Sadallah S, et al. Complement mediates the binding of HIV to erythrocytes. J Immunol 2004; 173:4236-4241. (Pubitemid 39280790)
74. Bánki Z, Wilflingseder D, Ammann CG, et al. Factor I-mediated processing of complement-fragments on HIV immune-complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells. J Immunol 2006; 177:3469-3476. (Pubitemid 44277868)
75. Joling P, Bakker LJ, Van Strijp JA, et al. Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 1993; 150:1065-1073. (Pubitemid 23133687)
76. Kacani L, Prodinger WM, Sprinzl GM, et al. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 2000; 74:7997-8002. (Pubitemid 30641644)
77. Banki Z, Kacani L, Rusert P, et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. AIDS 2005; 19:481-486. (Pubitemid 40515851)
78. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. Annu Rev Microbiol 1996; 50:825-854.
79. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274:985-989. (Pubitemid 26398421)
80. Smith-Franklin BA, Keele BF, Tew JG, et al. Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fcγ receptors. J Immunol 2002; 168:2408-2414.
81. Chakrabarti L, Cumont MC, Montagnier L, Hurtrel B. Kinetics of primary SIV infection in lymph nodes. J Med Primatol 1994; 23:117-1124.
82. Hurtrel B, Chakrabarti L, Hurtrel M, et al. Early events in lymph nodes during infection with SIV and FIV. Res Virol 1994; 145:221-227. (Pubitemid 24244522)
83. Stahl-Hennig C, Steinman RM, Tenner-Racz K, et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 1999; 285:1261-1265. (Pubitemid 29398612)
84. Milush JM, Kosub D, Marthas M, et al. Rapid dissemination of SIV following oral inoculation. AIDS 2004; 18:2371-2380. (Pubitemid 40065904)
85. Heath SL, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995; 377:740-744.
86. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276:960-964. (Pubitemid 27209096)
87. Sattentau Q. Correlates of antibody-mediated protection against HIV infection. Curr Opin HIV AIDS 2008; 3:368-374.
88. Bouhlal H, Chomont N, Haeffner-Cavaillon N, et al. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 2002; 169:3301-3306. (Pubitemid 35013178)
89. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001; 3:227-233. (Pubitemid 32434310)
90. Stoiber H, Soederholm A, Wilflingseder W, et al. Complement and antibodies: a dangerous liaison in HIV infection? Vaccine 2008; 30 (26 Suppl 8):179-185.